Anzeige
Mehr »
Login
Donnerstag, 03.04.2025 Börsentäglich über 12.000 News von 693 internationalen Medien
Warum Almonty Industries zum Schlüsselplayer für NATO-Staaten wird
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40GYJ | ISIN: US43906K2096 | Ticker-Symbol:
NASDAQ
03.04.25
18:24 Uhr
0,874 US-Dollar
-0,072
-7,57 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
HOOKIPA PHARMA INC Chart 1 Jahr
5-Tage-Chart
HOOKIPA PHARMA INC 5-Tage-Chart

Aktuelle News zur HOOKIPA PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
21.02.Poolbeg slumps as Hookipa merger is called off18
21.02.Poolbeg shares slide as Hookipa terminates takeover talks5
21.02.Poolbeg Pharma shares plummet as Hookipa walks away from possible bid4
21.02.Poolbeg Pharma PLC - Termination of proposed combination with HOOKIPA5
20.02.Hookipa Pharma rules out making offer for Poolbeg Pharma8
20.02.HOOKIPA Pharma Inc. - 8-K, Current Report-
20.02.US biotech Hookipa retracts merger plans with UK company4
20.02.HOOKIPA Pharma Inc. (";HOOKIPA") Statement regarding potential combination for Poolbeg Pharma plc ("Poolbeg")191NEW YORK and VIENNA, Austria, Feb. 20, 2025 (GLOBE NEWSWIRE) -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE...
► Artikel lesen
HOOKIPA PHARMA Aktie jetzt für 0€ handeln
30.01.HOOKIPA completes enrollment for HIV vaccine trial5
30.01.HOOKIPA Pharma Inc.: HOOKIPA Pharma Announces Enrollment Completion of Phase 1b Clinical Trial Evaluating HB-500 for the Treatment of HIV213HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of a curative regimen for human immunodeficiency virus...
► Artikel lesen
29.01.HOOKIPA Pharma Inc. - 8-K, Current Report1
10.01.HOOKIPA Pharma Inc. - 8-K, Current Report4
10.01.IN BRIEF: Poolbeg Pharma notes Gilead interest in Hookipa fundraise16
10.01.Poolbeg Pharma says Gilead in favour of its combination with Hookipa11
10.01.Poolbeg Pharma plc and HOOKIPA Pharma Inc.: Update on Potential Combination of Poolbeg and HOOKIPA156NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION....
► Artikel lesen
10.01.Poolbeg Pharma PLC - Update Potential Combination of Poolbeg & HOOKIPA7
08.01.HOOKIPA Pharma Inc.: HOOKIPA Pharma Inc - FORM 8 (OPD)5
08.01.HOOKIPA Pharma discloses position in takeover code filing8
07.01.HOOKIPA Pharma Inc.: HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements136NEW YORK and VIENNA, Austria, Jan. 07, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, "HOOKIPA", the "Company"), a clinical-stage biopharmaceutical company developing next generation...
► Artikel lesen
07.01.Form 8.3 - The Vanguard Group, Inc.: HOOKIPA Pharma Inc.316DJ Form 8.3 - The Vanguard Group, Inc.: HOOKIPA Pharma Inc. The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: HOOKIPA Pharma Inc. 07-Jan-2025 / 14:03 GMT/BST =----------------------------------------------------------------------------------------------------------------------...
► Artikel lesen
Seite:  Weiter >>
48 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1